Download full-text PDF |
Source |
---|
Cureus
November 2024
Pharmacology, Sir Seewoosagur Ramgoolam Medical College, Belle Rive, MUS.
Alendronate, a second-generation bisphosphonate, remains the first-line therapeutic option for postmenopausal osteoporosis. It acts on the bone resorbing osteoclasts causing their apoptosis. This is achieved by producing toxic adenosine triphosphate (ATP) analogues and interfering with the mevalonate pathway.
View Article and Find Full Text PDFEur J Endocrinol
November 2024
Department of Rheumatology, Amsterdam University Medical Center, Amsterdam 1081HV, The Netherlands.
AACE Clin Case Rep
May 2024
Department of Endocrinology and Metabolism, Westchester Medical Center, Valhalla, New York.
Osteoporos Int
December 2024
Mary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia.
Unlabelled: Sequential romosozumab-to-alendronate or sequential teriparatide-to-alendronate can be a cost-effective treatment option for postmenopausal women at very high risk of fracture.
Purpose: To estimate the 10-year probability of a major osteoporotic fracture (MOF) at which sequential treatment with romosozumab or teriparatide followed by alendronate, compared with alendronate alone, becomes cost-effective in a UK setting.
Methods: A microsimulation model with a Markov structure was used to simulate fractures, costs, and quality-adjusted life years (QALYs), in women receiving sequential treatment with either romosozumab or teriparatide followed by alendronate, compared with alendronate alone.
Osteoporos Int
December 2024
Soen Orthopaedics, Osteoporosis and Rheumatology Clinic, Kobe, Hyogo, Japan.
Unlabelled: The association of renal function with fracture incidence during teriparatide or alendronate treatment in elderly Japanese women was examined. Fracture incidence differed by fracture type, renal function, and treatment protocol. The results provide important information on pharmacotherapy in clinical practice for osteoporosis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!